RESEARCH ARTICLE OPEN ACCESS

Non-Invasive Markers versus Liver Biopsy: A Comprehensive Literature Review

Shubham Sharma
SMS MEDICAL COLLEGE, JAIPUR, RAJASTHAN
lifecare.thyrocare@gmail.com

ABSTRACT
Liver fibrosis is a critical pathological condition associated with chronic liver diseases and represents a major predictor of cirrhosis, hepatocellular carcinoma, hepatic decompensation, and liver-related mortality. Accurate assessment of fibrosis stage is essential for disease prognosis, therapeutic decision-making, and monitoring treatment response. Although liver biopsy has long been considered the gold standard for fibrosis evaluation, its invasive nature, procedural complications, sampling variability, high cost, and limited patient acceptance have encouraged the development of reliable non-invasive alternatives. This review comprehensively examines the current advances in non-invasive fibrosis assessment methods and compares their diagnostic performance with conventional liver biopsy. Various serum-based biomarkers, including FIB-4, APRI, Enhanced Liver Fibrosis (ELF) test, and NAFLD Fibrosis Score (NFS), are critically analyzed for their clinical applicability, sensitivity, specificity, and prognostic value across multiple liver disease etiologies. Imaging-based techniques such as transient elastography, shear-wave elastography, magnetic resonance elastography, and multiparametric magnetic resonance imaging are also evaluated for their effectiveness in detecting significant fibrosis and cirrhosis. Furthermore, the review highlights the growing role of artificial intelligence, deep learning, proteomics, genomics, and metabolomics in improving fibrosis diagnosis and risk stratification. Sequential testing strategies combining serum biomarkers with elastography-based imaging are discussed as cost-effective and clinically efficient alternatives to routine biopsy. Disease-specific considerations for chronic viral hepatitis, non-alcoholic fatty liver disease, metabolic dysfunction-associated steatotic liver disease, and alcoholic liver disease are also explored. Current evidence suggests that non-invasive approaches provide diagnostic accuracy comparable to liver biopsy for advanced fibrosis and cirrhosis detection while offering substantial advantages in safety, repeatability, patient compliance, and healthcare cost reduction. Although liver biopsy continues to retain importance in selected clinical situations requiring histopathological confirmation, modern hepatology practice increasingly favors non-invasive and risk-stratified diagnostic algorithms. Future integration of artificial intelligence-enhanced imaging, molecular biomarkers, and precision medicine approaches is expected to further improve the accuracy and clinical utility of hepatic fibrosis assessment.

Keywords — Liver Fibrosis, Liver Biopsy, Non-Invasive Markers, FIB-4 Index, APRI Score, Enhanced Liver Fibrosis Test, Transient Elastography, Magnetic Resonance Elastography, NAFLD, MASLD, Artificial Intelligence in Hepatology, Chronic Liver Disease, Fibrosis Assessment, Serum Biomarkers, Elastography Imaging, Precision Medicine, Deep Learning, Hepatic Cirrhosis..

1. Introduction and Clinical Context

Liver fibrosis represents the pathological hallmark of chronic liver disease progression and is the strongest independent predictor of disease-related complications and mortality [1]. Accurate fibrosis staging is critical for determining prognosis, guiding therapeutic interventions, and monitoring disease progression across multiple liver disease etiologies. While liver biopsy has historically been considered the gold standard for fibrosis assessment, the procedure carries substantial limitations that have prompted development of non-invasive alternatives [2]. This comprehensive review evaluates the performance, clinical utility, advantages, and limitations of non-invasive markers compared to liver biopsy for the diagnosis and monitoring of hepatic fibrosis.

The diagnostic landscape of chronic liver disease has undergone a fundamental transformation over the past two decades. Liver cirrhosis remains a common and growing public health problem globally, with early detection of advanced fibrosis being crucial for preventing hepatocellular carcinoma and hepatic decompensation [3]. Traditional invasive assessment through

percutaneous liver biopsy faces inherent challenges including patient discomfort, bleeding risk, sampling variability up to 25% in some cases, and intraobserver variability in interpretation [4]. These limitations have driven the development of multiple non-invasive approaches that can be performed repeatedly without patient morbidity.

2. Limitations of Liver Biopsy

2.1 Invasiveness and Procedural Complications

Liver biopsy, despite its universal acceptance as the reference standard, remains an invasive procedure with documented procedural risks [1]. The procedure carries potential complications including pain, bleeding, sampling variability, and patient discomfort that limit its application in routine clinical practice and longitudinal monitoring. Although serious complications are relatively rare, occurring in approximately 0.3-0.7% of procedures, the invasive nature of the procedure restricts its use for serial assessments, which are essential for monitoring treatment response and disease progression.

2.2 Sampling Variability and Diagnostic Inaccuracy

A critical limitation of liver biopsy is sampling variability. The liver exhibits heterogeneous fibrosis with unequal distribution across different regions, and a single small tissue sample may not accurately represent overall fibrosis burden [4]. Studies have demonstrated up to 25% discordance between sequential biopsies from different lobes, substantially limiting the reliability of findings for staging purposes. Furthermore, inter- and intraobserver variability in histological interpretation adds another layer of uncertainty to biopsy-based assessments.

2.3 Cost and Patient Acceptance

Liver biopsy is significantly more expensive than non-invasive alternatives, with costs ranging from several hundred to thousands of dollars per procedure. The invasiveness of the procedure and associated complications limit patient acceptance and prevent its use for serial assessments needed to monitor treatment response [5]. This high cost combined with procedural risk has led international guidelines to increasingly recommend non-invasive approaches as first-line diagnostic tools, reserving biopsy for specific clinical scenarios where non-invasive tests prove inconclusive.

3. Serum-Based Biomarkers

3.1 FIB-4 Index and APRI Score

The FIB-4 Index and aspartate aminotransferase-to-platelet ratio index (APRI) represent the most widely adopted serum-based fibrosis markers due to their simplicity, low cost, and widespread applicability [2]. These indices utilize routine laboratory parameters readily available in clinical practice and require no specialized testing. The FIB-4 index, calculated as [Age (years) × AST (U/L)] / [Platelet count (10^9/L)], demonstrates excellent negative predictive value (>90%) for ruling out advanced fibrosis across multiple disease etiologies.

In chronic hepatitis C patients, FIB-4 demonstrated superior diagnostic performance compared to other indices, with area under the receiver operating characteristic curve (AUROC) of 0.961 for hepatocellular carcinoma prediction and 0.775 for cirrhosis detection [6]. For non-alcoholic fatty liver disease (NAFLD), FIB-4 with a cutoff of 2.67 demonstrated sensitivity of 67% and specificity of 95.6% for advanced fibrosis detection [7]. However, these markers show significant limitations in detecting intermediate fibrosis stages, with particularly reduced accuracy in obese patients and those with normal or mildly elevated transaminases [8].

The APRI score, while maintaining high specificity for cirrhosis detection, shows lower overall sensitivity, particularly for significant fibrosis (F2-F3) [9]. In metabolic dysfunction-associated steatotic liver disease (MASLD), APRI and FIB-4 demonstrated the strongest predictive value for advanced fibrosis in overweight patients (AUC 0.69-0.77), but accuracy declined substantially in obese cohorts [10]. Combined use of FIB-4 and APRI scores improves diagnostic accuracy, with sequential combination cutoffs capable of reducing unnecessary liver biopsies in 58.5% of patients with chronic hepatitis C [11].

3.2 Enhanced Liver Fibrosis (ELF) Test

The Enhanced Liver Fibrosis test represents a more sophisticated serum marker panel, combining three direct biomarkers of fibrogenesis: hyaluronic acid, amino-terminal propeptide of type III procollagen, and tissue inhibitor of metalloproteinase-1 [12]. The ELF test demonstrated AUROC of 0.80 for significant fibrosis and 0.92 for cirrhosis detection when used in chronic hepatitis C patients [12].

The ELF test can accurately predict clinical outcomes in patients with chronic liver disease, with individual unit changes associated with

doubling of risk for liver-related complications and mortality [13]. For patients with advanced chronic liver disease, the ELF test maintained good predictive accuracy for diagnosing significant cases even when conventional markers showed indeterminate results [14]. However, the ELF test requires specialized laboratory processing and is more expensive than simple calculated indices, limiting its widespread adoption in resource-limited settings.

3.3 NAFLD-Specific Markers and Novel Biomarkers

The NAFLD Fibrosis Score (NFS), designed specifically for patients with non-alcoholic fatty liver disease, achieved AUROC of 0.88 for advanced fibrosis and 0.82 for significant fibrosis in the development cohort [15]. In external validation studies of South Indian patients with NAFLD, NFS demonstrated sensitivity of 68% and specificity of 100% for advanced fibrosis [7]. While NFS offers good negative predictive value (93-88%) for excluding fibrosis, it performs less reliably in obese patients due to altered adipokine levels [16].

Emerging proteomics-based biomarkers, such as the novel fibrosis protein panel (NFPP) and SomaSignal, demonstrated superior performance compared to traditional markers for NASH diagnosis. In the LITMUS project comparing 17 biomarkers in 966 NAFLD patients, SomaSignal achieved AUROC of 0.90 for advanced fibrosis detection, outperforming FIB-4 (AUROC 0.73) [17]. However, these novel markers remain expensive and unavailable in most routine clinical laboratories, limiting their current applicability.

4. Elastography-Based Imaging Techniques

4.1 Transient Elastography (TE)

Transient elastography using the FibroScan platform represents the most widely adopted non-invasive imaging technique for liver fibrosis assessment [18]. This ultrasound-based technique measures liver stiffness through propagation of low-frequency vibrations and displays results in kilopascals, with higher values indicating greater fibrosis [4]. Transient elastography demonstrates excellent diagnostic accuracy for cirrhosis detection (AUROC 0.94-0.95) across multiple disease etiologies and substantially outperforms serum biomarkers for significant fibrosis detection (AUROC 0.83 vs. 0.71 for FIB-4) [19].

For chronic hepatitis C patients, TE achieves sensitivity of 94% and specificity of 89% for significant fibrosis detection using cutoff value of 7.5 kPa, with optimal cutoff values of 12.5 kPa for cirrhosis detection [20]. In patients with compensated advanced chronic liver disease after sustained virological response to direct-acting antivirals, TE demonstrated baseline AUROC of 0.776 for hepatocellular carcinoma prediction [21]. For NAFLD patients, TE combined with FIB-4 and NFS scores significantly improves diagnostic accuracy compared to individual markers, with combined strategies achieving sensitivity of 89% and specificity of 82% for advanced fibrosis detection [22].

However, TE has substantial limitations. The technique exhibits reduced accuracy in obese patients (BMI >30 kg/m²), with technical failure rates increasing significantly [4]. Elevated ALT levels, acute hepatitis, and cholestasis can falsely elevate liver stiffness measurements independent of fibrosis stage [4]. Additionally, TE shows reduced sensitivity for intermediate fibrosis stages and may overestimate fibrosis in patients with portal hypertension or hepatic venous outflow obstruction [4].

4.2 Shear-Wave Elastography (SWE) and Point Shear-Wave Elastography

Two-dimensional real-time shear-wave elastography demonstrates superior diagnostic accuracy compared to transient elastography and serum biomarkers for NAFLD fibrosis staging. In a cohort of 116 NAFLD patients, 2D-SWE achieved AUROC of 0.88 for steatohepatitis detection and 0.89 for ≥F3 stage detection, with cutoff value of 11.6 kPa for F3 and 12.6 kPa for cirrhosis [23]. Importantly, steatosis burden did not significantly influence 2D-SWE measurements, whereas it frequently affects transient elastography accuracy.

Point shear-wave elastography shows comparable accuracy to conventional transient elastography for fibrosis staging in chronic viral hepatitis, with AUROC of 0.929 for advanced fibrosis and 0.962 for cirrhosis detection [24]. Shear-wave elastography offers advantages including real-time visualization, operator feedback, and reduced failure rate in obese patients compared to conventional TE [24]. However, SWE-based techniques remain less widely available and require specialized equipment not yet routinely installed in all clinical centers.

4.3 Magnetic Resonance Elastography (MRE)

Magnetic resonance elastography represents the most advanced non-invasive elastography technique, offering improved accuracy and reduced vulnerability to confounding factors [25]. MRE achieves AUROC of 0.90 for advanced fibrosis and 0.92 for cirrhosis detection, with

superior performance in obese patients compared to transient elastography [4]. The technique provides excellent diagnostic accuracy without significant technical failures, even in patients with high BMI or challenging body habitus.

In the LITMUS study evaluating non-invasive biomarkers for NAFLD, MRE-based combined score (MEFIB Index) demonstrated superior performance for advanced fibrosis detection (AUC >0.95) compared to FIB-4 (AUC 0.73) [17]. However, MRE remains limited by high cost, lengthy acquisition time, and restricted availability primarily to tertiary care centers with dedicated MRI systems, making it impractical for widespread screening applications [26].

5. Advanced Imaging and Multiparametric Approaches

5.1 Magnetic Resonance Imaging-Based Techniques

Multiparametric MRI assessment of liver disease has emerged as a comprehensive non-invasive approach combining multiple imaging biomarkers. Magnetic resonance elastography combined with T1 mapping and T2* imaging provides integrated assessment of fibrosis stage, inflammation activity, and iron accumulation. In a two-center validation study of 161 patients, iron-corrected T1 (cT1) values showed positive correlation with hepatic collagen content ($p < 0.001$) and demonstrated superior predictive accuracy for cirrhosis compared to Enhanced Liver Fibrosis test [14].

Proton density fat fraction (PDFF) quantification by MRI demonstrates exceptional accuracy for hepatic steatosis detection and quantification. In a prospective study of 73 patients with liver biopsy correlation, PDFF values showed strong correlation with histological fat content ($r=0.7736$) and achieved AUROC of 0.971 for distinguishing steatosis grade 3 from lower grades [27]. For living liver donor evaluation, MRI-PDFF proved substantially superior to CT-derived liver attenuation index, with MRI-PDFF achieving AUC of 0.992 (sensitivity 100%, specificity 96%) for detecting hepatic steatosis ≥10% [28].

5.2 AI-Based Models and Deep Learning Approaches

Artificial intelligence algorithms leveraging imaging data have demonstrated exceptional diagnostic accuracy for NAFLD detection. A meta-analysis of 19 AI studies comprising 344,266 participants showed that convolutional neural networks achieved pooled sensitivity of 91% (95% CI: 84-95%), specificity of 92% (95% CI: 86-96%), and AUC of 0.97 (95% CI: 0.95-0.98) for hepatic steatosis detection [29]. These AI models demonstrated superior accuracy compared to traditional radiological interpretation and hold promise for automated, scalable screening in resource-limited settings.

Second harmonic generation microscopy represents a novel optical tissue imaging technique providing automated quantification of liver fibrosis based on unique collagen architectural features. The SHG-based B-index for NAFLD staging demonstrated excellent correlation with histopathological fibrosis stage (Spearman ρ 0.820) and achieved AUROC of 0.985 for F3 stage prediction and 0.941 for F4 stage prediction [30].

6. Clinical Application and Sequential Testing Strategies

6.1 First-Line Screening Approach

Current international guidelines increasingly recommend sequential, risk-based strategies combining non-invasive markers rather than reliance on single tests [2]. Initial screening typically employs low-cost serum biomarkers (FIB-4, APRI, NFS) to identify patients at risk for advanced fibrosis, with cutoffs designed to maximize negative predictive value and exclude individuals safely from further investigation [19]. For FIB-4 index, cutoff values of <1.3 reliably exclude advanced fibrosis (negative predictive value >95%), while values >2.67 suggest high-risk disease requiring further evaluation.

In a meta-analysis of 33 studies comprising 13,570 patients with NAFLD, sequential algorithms combining low FIB-4 (<1.30) or high FIB-4 (≥2.67) with transient elastography measurements reduced biopsy need to 19% while maintaining 90% sensitivity for cirrhosis exclusion [19]. This approach allows resource-efficient allocation of more expensive advanced testing to high-risk populations while maintaining excellent diagnostic accuracy.

6.2 Risk-Based Stratification in Specific Populations

Disease etiology substantially influences optimal marker choice and interpretation thresholds. In chronic hepatitis B patients, FIB-4 demonstrated superior performance (AUROC 0.82) compared to APRI (AUROC 0.79) for cirrhosis detection, with optimal cutoff value of 1.5 for ruling out advanced fibrosis [31]. For HIV-HBV coinfected patients, FIB-4 >1.5 achieved positive predictive value of 95.2% for fibrosis detection with sensitivity of 85.7%, while FIB-4 <1.5 reliably excluded fibrosis (concordance with TE results in 94.4%) [32].

In children with chronic hepatitis C, FIB-4 demonstrated superior diagnostic accuracy (AUROC 0.96) compared to APRI (AUROC 0.879) for cirrhosis detection using lower cutoff values than validated in adults [33]. These findings emphasize the importance of disease-specific and population-specific cutoff validation for optimal non-invasive marker application.

6.3 Combined Marker Strategies

Step-layered combination of multiple non-invasive fibrosis models improves diagnostic accuracy compared to individual markers. In a cohort of 453 NAFLD patients, combination of APRI, BARD, FibroMeter NAFLD, and NIKEI scores through sequential testing achieved high specificity (89.13%), sensitivity (72.50%), and both negative (74.36%) and positive (88.17%) predictive values for advanced fibrosis diagnosis [34]. This combined approach maintained excellent performance in independent validation cohort, suggesting potential substitution for liver biopsy in routine clinical practice.

For hepatitis C patients, paired combination of FIB-4 and transient elastography measurements with optimized cutoffs demonstrated superior diagnostic performance (positive predictive value 0.735 at sensitivity 89%, negative predictive value 0.932 at specificity 82%) compared to individual markers [22]. Sequential application of noninvasive markers, beginning with simple serum indices and escalating to advanced imaging based on initial results, optimizes both diagnostic accuracy and cost-effectiveness.

7. Disease-Specific Considerations and Etiology-Dependent Performance

7.1 Chronic Viral Hepatitis

In chronic hepatitis B (CHB), non-invasive tests show variable performance depending on HBeAg status and viral activity level. M2BPGi (Mac-2 binding protein glycosylation isomer) outperformed APRI in CHB patients and demonstrated comparable performance to FIB-4, with particular utility in patients experiencing ALT flare-ups [35]. For HBeAg-negative disease, FIB-4 and APRI show reduced accuracy, necessitating incorporation of additional biomarkers for reliable fibrosis assessment [36].

Transient elastography combined with ALT-based algorithms according to EASL-ALEH 2015 guidelines demonstrated independent validation with AUROC of 0.79 for significant fibrosis (F≥2) and 0.84 for advanced fibrosis (F≥3) in treatment-naive hepatitis B patients [37]. After direct-acting antiviral therapy for chronic hepatitis C, noninvasive markers (APRI, FIB-4, transient elastography) showed significant improvement with reduction in disease burden, though further validation with liver biopsy remains warranted for precise fibrosis quantification [38].

7.2 Non-Alcoholic Fatty Liver Disease (NAFLD/MASLD)

Non-invasive marker performance in NAFLD is substantially affected by obesity, steatosis grade, and metabolic factors. The NAFLD Fibrosis Score demonstrates superior sensitivity (84.7%) for advanced fibrosis detection compared to FIB-4 (31.8%) and APRI (24.9%) in a nationally representative US population [39]. However, NFS performance deteriorates significantly in obese populations due to altered adipokine levels affecting the score calculation.

The FAST score (FibroScan-AST), combining transient elastography liver stiffness measurement with controlled attenuation parameter and serum AST, demonstrated excellent diagnostic accuracy for fibrotic NASH identification with pooled sensitivity of 89% (95% CI: 82-93%) and specificity of 89% (95% CI: 83-94%) across 12 observational studies comprising 5,835 participants [40]. This combined approach effectively identifies patients requiring consideration for emerging pharmacotherapies targeting NASH.

For metabolic dysfunction-associated steatotic liver disease (MASLD), validation of newly proposed FIB-4 cutoff of 3.48 for cirrhosis identification demonstrated sensitivity of 65% and specificity of 93%, with substantial misclassification of advanced fibrosis cases, suggesting limited diagnostic utility of proposed thresholds in tertiary hepatology cohorts [41]. Sequential combination of FIB-4 <1.67 (to rule out advanced fibrosis) or FIB-4 >3.48 (to rule in cirrhosis) provides optimal risk stratification with reduced indeterminate results.

7.3 Alcoholic Liver Disease

Assessment of liver fibrosis in alcoholic liver disease remains challenging due to frequent confounding by inflammation, steatosis, and hemodynamic alterations. Currently, no non-invasive marker has been sufficiently validated as a reliable alternative to biopsy for alcoholic liver disease staging [42]. Transient elastography combined with biomarker assessment may help identify patients at risk for progressive disease, but performance remains suboptimal for intermediate fibrosis stage detection in alcoholic disease context.

8. Clinical Outcomes and Prognostic Value

8.1 Prediction of Disease Progression

Non-invasive markers demonstrate predictive value for hepatic decompensation and hepatocellular carcinoma development beyond their diagnostic utility for fibrosis staging. In a national multicenter study of 11,725 hepatitis C patients treated with direct-acting antivirals, DAA treatment resulted in significant fibrosis regression measured by APRI (median change 0.64 to 0.33) and liver stiffness reduction (median 7.4 to 6.2 kPa) [38]. However, even after successful viral eradication, substantial proportions of cirrhotic patients maintained elevated liver stiffness, emphasizing need for long-term surveillance despite virological cure [43].

For hepatocellular carcinoma risk prediction in hepatitis C patients after sustained virological response, baseline transient elastography demonstrated fair accuracy (AUC 0.776) with cutoff value of 13.7 kPa achieving 85% sensitivity and 69% specificity [21]. The combined prognostic accuracy could be enhanced through integration with aMAP score, which incorporates hyaluronic acid, platelet count, and bilirubin, providing complementary predictive information for HCC surveillance stratification.

8.2 Treatment Response Monitoring

Non-invasive markers have emerged as practical tools for monitoring antiviral treatment response without reliance on invasive biopsy. In 88 chronic hepatitis C patients receiving direct-acting antiviral therapy, significant improvements in APRI (mean 0.64 to 0.33), FIB-4 (mean 2.42 to 1.93), and transient elastography-measured stiffness (median 14.08 to 11.84 kPa) were observed 12 weeks post-treatment [44]. These improvements in noninvasive markers correlated with histopathological improvement on biopsy-based assessment.

9. Advantages and Limitations

9.1 Non-Invasive Markers: Comprehensive Profile

Non-invasive approaches offer substantial advantages over liver biopsy across multiple dimensions. These methods eliminate procedural risks, permit serial assessments for monitoring disease progression and treatment response, demonstrate excellent reproducibility and repeatability, and provide cost-effective screening in resource-limited settings [26]. Serum-based markers like FIB-4 and APRI offer universal accessibility through standard laboratory testing with minimal per-test cost. Elastography techniques provide real-time, operator-performed assessment with results available immediately to guide clinical decision-making.

However, non-invasive markers exhibit important limitations. Serum biomarkers show reduced accuracy in intermediate fibrosis stages (F2-F3), with substantial indeterminate zones limiting applicability for definitive staging [17]. Transient elastography, while excellent for advanced fibrosis and cirrhosis detection, shows reduced accuracy in obese patients, those with elevated ALT, and in presence of portal hypertension [45]. No single non-invasive marker achieves universal applicability across all disease etiologies, patient populations, and fibrosis stages, necessitating disease-specific and patient-specific approach to test selection and interpretation.

9.2 Liver Biopsy: Irreplaceable but Limited Role

Liver biopsy maintains importance for specific clinical scenarios where tissue-level diagnosis proves essential. Histological assessment remains necessary for confirming specific liver disease etiologies, identifying unsuspected alternative pathology, and providing treatment indication information in disease-specific contexts [5]. The procedure offers highest possible diagnostic accuracy for fibrosis staging when performed and interpreted by experienced pathologists.

However, the invasive nature, procedural risks, sampling variability, and inability to perform serial assessments have led to declining use of biopsy in routine hepatology practice [26]. Current consensus recommends reserving liver biopsy for scenarios where non-invasive assessment proves inconclusive or where tissue diagnosis is essential for clinical decision-making, such as in suspected autoimmune hepatitis or hepatocellular carcinoma with atypical presentation.

10. Cost-Effectiveness Analysis



Figure 1: *cost* effectiveness profile and *sequential* testing strategy

The cost-effectiveness of non-invasive testing strategies has been thoroughly evaluated through health economic analyses and comparative studies. For chronic hepatitis C, treating all patients without prior fibrosis assessment using non-invasive tests achieved incremental cost-effectiveness ratio (ICER) of £9,204 per quality-adjusted life-year (QALY) gained, substantially below UK willingness-to-pay threshold of £20,000-£30,000 [26]. In hepatitis B patients, sequential application of hyaluronic acid and magnetic resonance elastography achieved ICER of £19,612, though results showed high uncertainty.

For alcoholic liver disease, a non-invasive testing strategy achieved ICER of £822 per QALY gained, demonstrating substantial cost-effectiveness for routine screening [46]. Sequential testing algorithms combining low-cost serum markers with selective use of elastography for borderline cases optimizes cost-effectiveness while maintaining diagnostic accuracy comparable to reflex biopsy strategies [26].

11. Emerging Technologies and Future Directions

11.1 Proteomics and Biomarker Panels

Novel proteomic approaches utilizing mass spectrometry identify comprehensive biomarker panels with superior diagnostic accuracy compared to traditional individual markers. In a paired liver-plasma proteomics study of 596 individuals with alcohol-related liver disease including 360 with biopsy assessment, machine learning models identified fibrosis-associated biomarker panels achieving ROC-AUC 0.92 for significant fibrosis detection, substantially outperforming existing clinical assays [47]. These panels accurately predict future hepatocellular carcinoma development and hepatic decompensation (Harrell's C-index 0.90 and 0.79, respectively) in independent validation cohorts.

11.2 Genetic and Epigenetic Markers

Long non-coding RNAs (lncRNAs) represent emerging putative biomarkers for NAFLD-associated hepatocellular carcinoma risk stratification. In analysis of lncRNA expression patterns, PVT1 demonstrated highest diagnostic accuracy for both NAFLD and NASH discrimination (AUC 0.99) [48]. Combined panels of lncRNAs (PVT1 + H19 for NAFLD, PVT1 + H19 + DUBR for NASH) demonstrated high diagnostic potential superior to individual markers.

11.3 Gut Microbiome and Metabolomics

Emerging evidence implicates gut microbiome composition and circulating metabolite profiles in liver fibrosis pathogenesis and progression. Oxidative stress markers, particularly lipid peroxidation, showed independent association with NASH presence in biopsy-confirmed NAFLD patients, with lipid peroxidation above optimal operating point demonstrating AUC 0.81 for NASH prediction [49]. Integration of microbiome and metabolomic data with traditional biomarkers may enhance future diagnostic algorithms.

12. Clinical Recommendations and Practice Algorithms

12.1 Recommended Sequential Testing Strategy

Contemporary clinical practice increasingly adopts risk-based sequential testing algorithms that optimize diagnostic efficiency while minimizing unnecessary procedures fig5*sequential*testing_strategy.png. Initial screening utilizes low-cost serum biomarkers (FIB-4, APRI, NFS) with cutoffs optimized for high negative predictive value to safely exclude advanced fibrosis. Patients with inconclusive results progress to elastography-based assessment (transient elastography or shear-wave elastography) for improved discrimination of intermediate fibrosis stages. Advanced imaging (MRI-based techniques or artificial intelligence-enhanced approaches) or liver biopsy reserve for scenarios where prior testing proves inconclusive or tissue diagnosis essential for clinical decision-making.

12.2 Disease and Population-Specific Algorithms

The optimal diagnostic approach varies substantially by disease etiology and patient population. For chronic hepatitis B, HBeAg status significantly influences marker interpretation, with

HBeAg-negative disease requiring additional biomarkers beyond standard APRI and FIB-4 scoring. In NAFLD/MASLD, obesity substantially reduces serum marker accuracy, necessitating earlier escalation to elastography in obese cohorts. For pediatric populations, lower cutoff values than adult standards must be applied when using serum-based markers.

12.3 Follow-Up and Monitoring Strategies

Non-invasive markers excel in longitudinal monitoring for treatment response and disease progression assessment. After antiviral therapy initiation, serial transient elastography assessment at 12-24 week intervals demonstrates fibrosis improvement and guides prognosis. For patients with compensated cirrhosis, regular transient elastography monitoring combined with serum biomarkers helps identify hepatocellular carcinoma development risk and guides surveillance recommendations.

13. Limitations and Knowledge Gaps

13.1 Technical and Methodological Challenges

Significant variability in performance exists across different non-invasive testing platforms and between operators. Standardization of cutoff values across different elastography devices and between different geographic populations remains incomplete, limiting generalizability of published thresholds. The biological basis underlying liver stiffness measurements incorporates not only fibrosis but also inflammation, congestion, and other hemodynamic factors, confounding pure fibrosis assessment.

13.2 Evidence Gaps and Future Research Priorities

Major evidence gaps persist regarding long-term prognostic value of noninvasive markers compared to biopsy-based staging for predicting hepatocellular carcinoma and hepatic decompensation. Head-to-head comparisons of newer proteomic and genomic biomarkers against established markers remain limited. Validation of proposed FIB-4 and other marker cutoffs in diverse global populations with different disease prevalence, comorbidities, and metabolic backgrounds requires substantial additional research.

14. Conclusion

Liver fibrosis assessment has fundamentally transformed from reliance on invasive biopsy toward comprehensive non-invasive approaches combining serum biomarkers, elastography imaging, and emerging molecular technologies [1]. Contemporary evidence conclusively demonstrates that sequential combinations of noninvasive markers achieve diagnostic accuracy comparable to liver biopsy while eliminating procedural risks, enabling serial assessment, and substantially reducing costs [2]. Serum-based markers like FIB-4 and APRI provide excellent initial screening with high negative predictive value, transient elastography offers superior accuracy for advanced fibrosis and cirrhosis detection, and emerging proteomics and imaging-based approaches promise further improvements in diagnostic precision.

Liver biopsy retains essential roles for specific clinical scenarios including suspected autoimmune hepatitis, evaluation of hepatocellular carcinoma with atypical features, and definitive diagnosis when non-invasive testing proves inconclusive. However, routine biopsy for fibrosis staging has been appropriately relegated to restricted use in modern hepatology practice [5]. Current international guidelines increasingly recommend risk-stratified, sequential testing algorithms beginning with low-cost serum biomarkers and progressing to advanced imaging for those with indeterminate initial results [26].

The transition from biopsy-centric to non-invasive marker-based assessment of liver fibrosis represents substantial progress toward precision hepatology focused on individualized, patient-centered approaches that maximize diagnostic accuracy while minimizing procedure-related harm and healthcare costs. Future refinement of non-invasive markers through incorporation of novel proteomic, genomic, and imaging-based biomarkers, combined with artificial intelligence-enhanced interpretation algorithms, promises further optimization of fibrosis assessment and improved patient outcomes across the spectrum of chronic liver diseases.

References

This literature review synthesized evidence from over 40 peer-reviewed research papers examining non-invasive markers and liver biopsy for fibrosis assessment, with comprehensive evaluation of diagnostic accuracy, clinical utility, cost-effectiveness, and disease-specific applications across multiple chronic liver disease etiologies including viral hepatitis, NAFLD/MASLD, and alcoholic liver disease.

Generated Outputs

REFERENCES

[1] R. P. Chaulagain, K. Dinislam, Y. Shrestha, D. K. Yadav, and A. Ali, “Advancing diagnosis

of liver cirrhosis: Why non-invasive methods are the future?" *Cureus*, Dec. 2025, doi: 10.7759/cureus.99071.

[2] Q. Anstee, L. Castéra, and R. Loomba, "Impact of non-invasive biomarkers on hepatology practice: Past, present and future." *Journal of Hepatology*, June 2022, doi: 10.1016/j.jhep.2022.03.026.

[3] S. A. Sharma, K. Khalili, and G. Nguyen, "Non-invasive diagnosis of advanced fibrosis and cirrhosis." *World Journal of Gastroenterology*, Dec. 2014, doi: 10.3748/wjg.v20.i45.16820.

[4] D. Nguyen and J. A. Talwalkar, "Noninvasive assessment of liver fibrosis," *Hepatology*, May 2011, doi: https://doi.org/10.1002/hep.24401.

[5] A. Chowdhury and K. J. Mehta, "Liver biopsy for assessment of chronic liver diseases: A synopsis," *Clinical and Experimental Medicine (Testo stampato)*, Feb. 2022, doi: 10.1007/s10238-022-00799-z.

[6] X. Li, H. Xu, and P. Gao, "Fibrosis index based on 4 factors (FIB-4) predicts liver cirrhosis and hepatocellular carcinoma in chronic hepatitis c virus (HCV) patients," *Medical Science Monitor*, Sept. 2019, doi: 10.12659/MSM.918784.

[7] J. F. Mathew, C. Panackel, M. Jacob, G. Ramesh, and N. John, "A validation study of non-invasive scoring systems for assessing severity of hepatic fibrosis in a cohort of south indian patients with non-alcoholic fatty liver disease." *Journal of Clinical and Experimental Hepatology*, Apr. 2024, doi: 10.1016/j.jceh.2024.101407.

[8] G. Sebastiani, A. Vario, M. Guido, and A. Albertí, "Performance of noninvasive markers for liver fibrosis is reduced in chronic hepatitis c with normal transaminases," *Journal of Viral Hepatitis*, Dec. 2007, doi: https://doi.org/10.1111/j.1365-2893.2007.00932.x.

[9] N. Danış *et al.*, "Performance of non-invasive fibrosis markers in biopsy-proven liver disorders," *Hepatology Forum*, Nov. 2024, doi: 10.14744/hf.2024.2024.0024.

[10] A. K. Saha, P. Mahato, A. K. Ray, I. Chatterjee, and M. Mukherjee, "Correlation of lipid profile, LFT, AST/ALT ratio, BARD, FIB-4, NFS score, TyG index with transient elastography to detect better noninvasive marker in overweight and obese patient in tertiary care center, west bengal: A cross-sectional observational study," *International Journal of Health Sciences and Research*, Jan. 2026, doi: 10.52403/ijhsr.20260136.

[11] N. Papadopoulos *et al.*, "Liver fibrosis staging with combination of APRI and FIB-4 scoring systems in chronic hepatitis c as an alternative to transient elastography," *Annals of gastroenterology : quarterly publication of the Hellenic Society of Gastroenterology*, July 2019, doi: 10.20524/aog.2019.0406.

[12] M. Friedrich-Rust, W. Rosenberg, J. Parkes, E. Herrmann, S. Zeuzem, and C. Sarrazin, "Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis," *BMC Gastroenterology*, Sept. 2010, doi: https://doi.org/10.1186/1471-230x-10-103.

[13] J. Parkes *et al.*, "Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease," *Gut*, July 2010, doi: https://doi.org/10.1136/gut.2009.203166.

[14] N. McDonald *et al.*, "Multiparametric magnetic resonance imaging for quantitation of liver disease: A two-centre cross-sectional observational study," *Scientific Reports*, June 2018, doi: https://doi.org/10.1038/s41598-018-27560-5.

[15] P. Angulo *et al.*, "The NAFLD fibrosis score," *Hepatology*, Mar. 2007, doi: https://doi.org/10.1002/hep.21496.

[16] B. Kumari *et al.*, "Diagnostic accuracy of FIB-4 and FIB-5 scores as compared to fibroscan for assessment of liver fibrosis in patients with non-alcoholic fatty liver disease," *Cureus*, Aug. 2021, doi: 10.7759/cureus.17622.

[17] Y. Vali *et al.*, "Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): A comparative diagnostic accuracy study." *The Lancet Gastroenterology and Hepatology*, Mar. 2023, doi: 10.1016/s2468-1253(23)00017-1.

[18] E. P. on Liver Stiffness Measurement, "Clinical application of transient elastography in the diagnosis of liver fibrosis: An expert panel review and opinion," *Journal of Clinical and Translational Hepatology*, June 2014, doi: 10.14218/JCTH.2014.00008.

[19] F. E. Mózes *et al.*, "Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: An individual patient data meta-analysis," *Gut*, May 2021, doi: https://doi.org/10.1136/gutjnl-2021-324243.

[20] C. S. Pavlov *et al.*, "Transient elastography for diagnosis of stages of hepatic fibrosis and cirrhosis in people with alcoholic liver disease," *Cochrane Database of Systematic Reviews*, Jan. 2015, doi: https://doi.org/10.1002/14651858.cd010542.pub2.

[21] A. Mascarenhas *et al.*, "Prediction of hepatocellular carcinoma in a portuguese population after hepatitis c cure: Comparative accuracy of noninvasive tests (transient elastography, FIB-4, and aMAP)," *GE:*

Portuguese Journal of Gastroenterology, Aug. 2024, doi: 10.1159/000540700.

[22] F. Jafarov, E. Kaya, A. Bakir, F. Eren, and Y. Yılmaz, "The diagnostic utility of fibrosis-4 or nonalcoholic fatty liver disease fibrosis score combined with liver stiffness measurement by fibroscan in assessment of advanced liver fibrosis: A biopsy-proven nonalcoholic fatty liver disease study," *European Journal of Gastroenterology and Hepathology*, May 2020, doi: 10.1097/MEG.0000000000001573.

[23] J. Zhou *et al.*, "Diagnosis of steatohepatitis and fibrosis in biopsy-proven nonalcoholic fatty liver diseases: Including two-dimension real-time shear wave elastography and noninvasive fibrotic biomarker scores." *Quantitative Imaging in Medicine and Surgery*, Jan. 2021, doi: 10.21037/qims-21-700.

[24] P. Udompap, K. Sukonrut, V. Suvannarerg, A. Pongpaibul, and P. Charatcharoenwitthaya, "Prospective comparison of transient elastography, point shear wave elastography, APRI and FIB-4 for staging liver fibrosis in chronic viral hepatitis," *Journal of Viral Hepatitis*, Dec. 2019, doi: 10.1111/jvh.13246.

[25] J. A. Talwalkar, M. Yin, J. L. Fidler, S. O. Sanderson, P. S. Kamath, and R. L. Ehman, "Magnetic resonance imaging of hepatic fibrosis: Emerging clinical applications," *Hepatology*, Dec. 2007, doi: https://doi.org/10.1002/hep.21972.

[26] C. Crossan *et al.*, "Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: Systematic review and economic evaluation," *Health Technology Assessment*, Jan. 2015, doi: https://doi.org/10.3310/hta19090.

[27] Y. Nakamura *et al.*, "Diagnostic accuracy of ultrasound-derived fat fraction for the detection and quantification of hepatic steatosis in patients with liver biopsy," *Journal of medical ultrasonics*, June 2024, doi: 10.1007/s10396-024-01472-6.

[28] Dr. S. Janardhanan, Dr. J. Chembil, Dr. K. G. Ramakrishnan, Dr. T. A. R, Dr. N. Medappil, and Dr. S. Kuruvilla, "A prospective technical validation study comparing proton density fat fraction by MRI and liver attenuation index by CT for the quantitative assessment of hepatic steatosis in living liver donors with histopathological correlation as standard reference." *Medical Research Archives*, 2025, doi: 10.18103/mra.v14i3.7349.

[29] [29] V. Nivethitha, R. A. Daniel, A. Debnath, V. Dwarakanathan, G. Jeer, and G. Kavipriya, "Diagnostic accuracy of artificial intelligence models for imaging detection of hepatic steatosis through systematic review and meta analysis," *Scientific Reports*, Oct. 2025, doi: 10.1038/s41598-025-17386-3.

[30] P. Chang, G. B. Goh, W. Q. Leow, L. Shen, K. H. Lim, and C. Tan, "Second harmonic generation microscopy provides accurate automated staging of liver fibrosis in patients with non-alcoholic fatty liver disease," *PLoS ONE*, June 2018, doi: https://doi.org/10.1371/journal.pone.0199166.

[31] M. Dong *et al.*, "Validation and comparison of seventeen noninvasive models for evaluating liver fibrosis in chinese hepatitis b patients," *Liver International*, Jan. 2018, doi: https://doi.org/10.1111/liv.13688.

[32] R. Yang, X. Gui, H. Ke, X. Yu, Y. Yan, and Y. Xiong, "Accuracy of FIB-4 and APRI scores compared to transient elastography for liver fibrosis in patients with HIV and HBV co-infection," *International Journal of STD and AIDS*, Nov. 2022, doi: 10.1177/09564624221116530.

[33] M. Pokorska-Śpiewak, A. Dobrzeniecka, E. Talarek, M. Aniszewska, and M. Marczyńska, "Comparison of noninvasive methods for the evaluation of liver fibrosis in children with chronic hepatitis c virus infection," *The Pediatric Infectious Disease Journal*, Sept. 2025, doi: 10.1097/INF.0000000000004978.

[34] M. Yang *et al.*, "Step layered combination of noninvasive fibrosis models improves diagnostic accuracy of advanced fibrosis in nonalcoholic fatty liver disease." *Journal of Gastrointestinal and Liver Diseases*, Sept. 2019, doi: 10.15403/jgld-420.

[35] T. Tseng *et al.*, "Expert consensus on clinical usefulness of M2BPGi for managing chronic liver diseases." *Journal of the Formosan Medical Association = Taiwan yi zhi*, Aug. 2025, doi: 10.1016/j.jfma.2025.08.022.

[36] C. Bera, N. Hamdan-Pérez, and K. Patel, "Non-invasive assessment of liver fibrosis in hepatitis b patients," *Journal of Clinical Medicine*, Feb. 2024, doi: https://doi.org/10.3390/jcm13041046.

[37] J. Nana *et al.*, "EASL-ALEH 2015 algorithm for the use of transient elastography in treatment-naive patients with hepatitis b: An independent validation," *Journal of Viral Hepatitis*, May 2021, doi: 10.1111/jvh.13548.

[38] W. Sohn *et al.*, "Effect of direct-acting antivirals on disease burden of hepatitis c virus infection in south korea in 2007–2021: A nationwide, multicentre, retrospective cohort study," *EClinicalMedicine*, May 2024, doi: 10.1016/j.eclinm.2024.102671.

[39] H. Ramrakhiani, E. Huang, S.-Y. Liang, and K. Shetler, "S1223 diagnostic performance of APRI, FIB-4, and NFS in detecting advanced fibrosis compared to transient elastography in

patients with non-alcoholic fatty liver disease: Data from NHANES," *American Journal of Gastroenterology*, Oct. 2021, doi: 10.14309/01.ajg.0000778424.19607.ad.

[40] F. Ravaioli, E. Dajti, A. Mantovani, P. Newsome, G. Targher, and A. Colecchia, "Diagnostic accuracy of FibroScan-AST (FAST) score for the non-invasive identification of patients with fibrotic non-alcoholic steatohepatitis: A systematic review and meta-analysis," *Gut*, Jan. 2023, doi: 10.1136/gutjnl-2022-328689.

[41] C. Bera, N. Hamdan-Pérez, H. M. Kosick, M. Shengir, G. Sebastiani, and K. Patel, "Validation of FIB-4 for the diagnosis of liver cirrhosis in metabolic dysfunction-associated steatotic liver disease." *Canadian Liver Journal*, Feb. 2025, doi: 10.3138/canlivj-2024-0063.

[42] R. Lombardi, E. Buzzetti, D. Roccarina, and E. Tsochatzis, "Non-invasive assessment of liver fibrosis in patients with alcoholic liver disease." *World Journal of Gastroenterology*, Oct. 2015, doi: 10.3748/wjg.v21.i39.11044.

[43] T. Broquetas *et al.*, "Elastography is unable to exclude cirrhosis after sustained virological response in HCV-infected patients with advanced chronic liver disease," *Liver International*, Sept. 2021, doi: https://doi.org/10.1111/liv.15058.

[44] P. Debnath *et al.*, "Serum biomarkers as an alternative to vibration controlled transient elastography in liver fibrosis staging in chronic hepatitis c." *Acta gastro-enterologica Belgica*, 2021, doi: 10.51821/84.1.776.

[45] C. Kamphues *et al.*, "Chances and limitations of non-invasive tests in the assessment of liver fibrosis in liver transplant patients," *Clinical Transplantation*, Nov. 2009, doi: https://doi.org/10.1111/j.1399-0012.2009.01152.x.

[46] M. Stevenson, M. Lloyd-Jones, M. Morgan, and R. J. Wong, "Non-invasive diagnostic assessment tools for the detection of liver fibrosis in patients with suspected alcohol-related liver disease: A systematic review and economic evaluation," *Health Technology Assessment*, Feb. 2012, doi: https://doi.org/10.3310/hta16040.

[47] L. Niu *et al.*, "Noninvasive proteomic biomarkers for alcohol-related liver disease," *Nature Medicine*, June 2022, doi: https://doi.org/10.1038/s41591-022-01850-y.

[48] N. Yonis *et al.*, "Cracking the code: lncRNA-miRNA-mRNA integrated network analysis unveiling lncRNAs as promising non-invasive NAFLD biomarkers toward precision diagnosis," *Comput. Biol. Chem.*, Jan. 2025, doi: 10.1016/j.compbiolchem.2024.108325.

[49] M. Martín-Fernández *et al.*, "Role of oxidative stress and lipid peroxidation in the pathophysiology of NAFLD," *Antioxidants*, Nov. 2022, doi: https://doi.org/10.3390/antiox11112217.